A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA™

This study will investigate the safety and efficacy of MK-0518 versus efavirenz, in combination with TRUVADA, as a therapy for Human Immunodeficiency Virus (HIV)-infected patients not previously treated.

Inclusion Criteria:

• Participant is a male or female at least 18 years of age
• Participant is HIV positive
• Participant is naïve to antiretroviral therapy (ART) and has not received any ART

Exclusion Criteria:

• Participant has received approved or experimental antiretroviral agents in the past
• Participant has been treated for a viral infection other than HIV such as hepatitis B virus infection with an agent that is active against HIV including but not limited to adefovir or lamivudine (= 7 days total)
• Participant has documented resistance to tenofovir, emtricitabine, and/or efavirenz
• Participant has used another experimental HIV-integrase inhibitor
• Participant has a current (active) diagnosis of acute hepatitis due to any cause
• Participants with chronic hepatitis including chronic hepatitis B and/or C may enter the study as long as they have stable liver function tests